ARQT Stock Overview
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Arcutis Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.18 |
| 52 Week High | US$13.17 |
| 52 Week Low | US$1.76 |
| Beta | 1.18 |
| 11 Month Change | 22.50% |
| 3 Month Change | 22.36% |
| 1 Year Change | 441.49% |
| 33 Year Change | -42.58% |
| 5 Year Change | n/a |
| Change since IPO | -53.30% |
Recent News & Updates
Recent updates
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Nov 15Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry
Sep 23
Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
Aug 22Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Jul 17Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing
Jun 21Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
May 24Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory
May 20Arcutis Biotherapeutics: Betting Big On Zoryve
May 01New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Apr 25Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
Mar 03Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Mar 02Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up
Feb 28Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Jan 31Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%
Oct 23Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Aug 13Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57
Aug 11Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02Shareholder Returns
| ARQT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.8% | -7.5% | -1.2% |
| 1Y | 441.5% | 14.1% | 30.4% |
Return vs Industry: ARQT exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: ARQT exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| ARQT volatility | |
|---|---|
| ARQT Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ARQT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ARQT's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 296 | Frank Watanabe | www.arcutis.com |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis.
Arcutis Biotherapeutics, Inc. Fundamentals Summary
| ARQT fundamental statistics | |
|---|---|
| Market cap | US$1.18b |
| Earnings (TTM) | -US$195.53m |
| Revenue (TTM) | US$138.71m |
8.6x
P/S Ratio-6.1x
P/E RatioIs ARQT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARQT income statement (TTM) | |
|---|---|
| Revenue | US$138.71m |
| Cost of Revenue | US$14.47m |
| Gross Profit | US$124.24m |
| Other Expenses | US$319.77m |
| Earnings | -US$195.53m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.67 |
| Gross Margin | 89.57% |
| Net Profit Margin | -140.97% |
| Debt/Equity Ratio | 130.6% |
How did ARQT perform over the long term?
See historical performance and comparison